Nov. 12 at 1:48 AM
$ALT My take post-AASLD, Pemvi is a master metabolic regulator, outstanding Scientific progress:
1- GLP-1 class leading MASH RESOLUTION at 24W
2- Higher MASH RES. than all but one of leading FGF21's (essentially statistically tied)
3- FDA requires single trad EP in P3 for approval (see #1), Pemvi stat sig at 24W already below p<0.0001, remarkable
4- EU has approved PathAI, FDA currently reviewing
5- Powerful Stat. Sig anti-Fibrosis per leading DP/AI HistoP technology
6- ABSOLUTE trad. Path Fibro very strong, basically FGF21 like (Placebo values were outlier IMO); FGF21 is downstream of GCG biologically (Pemvi eff. shows that)
7- DP/AI will play KEY role characterizing drugs from here on out,
$AKRO $MDGL utilizing
8- NITs & composite biomarkers WILL be way MASH is managed in the field; benefits drug candidate w/ PEMVI's broad biological profile
9- PEMVI WL w/ Lean Mass + Metabolism is major+ for Scripts/Market share potential
10- Excellent safety profile to date
Long ALT, not med/inv advice
